Orexo R&D Day 2026
A day for investors, analysts and media
During the day, CEO Nikolaj Sørensen and the management team will outline Orexo’s updated strategy and R&D priorities following the divestment of Zubsolv® in the US, including how the company’s proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The program will also feature expert perspectives from Mark A. Smith, PhD, Davidson College, NC, US, on emerging threats linked to xylazine, medetomidine, and fentanyl combinations.
Agenda
| Time am CET | Topic or activity | Presenter |
|---|---|---|
| 9:00–9.30 | Registration and coffee. | |
| 9:30–9:45 | Shaping Orexo’s future: Strategic priorities and value creation. | Nikolaj Sørensen, President and CEO. |
| 9:45–10:00 | AmorphOX: A unique opportunity to transform drug delivery of biomolecules from unstable injectables to convenient nasal or tablet delivery in an established scalable commercial supply chain. | Robert Rönn, SVP and Head of R&D / Cecilia Coupland, SVP and Head of Operations. |
| 10:00–10:15 | AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships. | Robert Rönn, SVP and Head of R&D / Lisa Moore, SVP, Product and Portfolio Strategy. |
| 10:15–10:30 | OX640: Aiming for the best-in-class nasal epinephrine product improving stability, bioavailability and patient convenience to address the needs of severe allergy patients. | Robert Rönn / Lisa Moore. |
| 10:30–10:45 | Break. | |
| 10:45–11:00 | OX390: Developing the world’s first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine in collaboration with BARDA, a center within the US Department of Health and Human Services. | Edward Kim, SVP and Chief Medical Officer. |
| 11:00–11:15 | Expert perspectives: Why countermeasures are needed for the emerging threats from xylazine, medetomidine, and fentanyl combinations. | Mark A. Smith, PhD Davidson College, NC, US. |
| 11:15–11:30 | Building a viable business model through business development. | Fredrik Järrsten, EVP and CFO, Head of Business Development. |
| 11:30–12:00 | Q&A, incl closing remarks by CEO. | All presenters. |
| 12 pm | Lunch & networking. |
Notes: OX640 is a powder-based intranasal epinephrine product candidate in development for the emergency treatment of Type I allergic reactions; OX390 is a powder-based intranasal rescue medication candidate in development for adulterated overdoses. Neither product has been approved by any regulatory agency.
Contact person
